Literature DB >> 7762917

Manufacturing consensus, marketing truth: guidelines for economic evaluation.

R G Evans.   

Abstract

Mesh：

Year:  1995        PMID： 7762917     DOI： 10.7326/0003-4819-123-1-199507010-00010

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN： 0003-4819            Impact factor:   25.391


× No keyword cloud information.
  10 in total

Review 1.  Pharmacoeconomic evaluation of new treatments: efficacy versus effectiveness studies?

Authors:  C Bombardier; A Maetzel
Journal:  Ann Rheum Dis       Date:  1999-11       Impact factor: 19.103

Review 2.  Conflict of interest in industry-sponsored economic evaluations: real or imagined?

Authors:  M Barbieri; M F Drummond
Journal:  Curr Oncol Rep       Date:  2001-09       Impact factor: 5.075

3.  A reappraisal of economic evaluation of pharmaceuticals. Science or marketing?

Authors:  M F Drummond
Journal:  Pharmacoeconomics       Date:  1998-07       Impact factor: 4.981

Review 4.  The costs of epilepsy and cost-based evaluations of anticonvulsants.

Authors:  W G Johnson
Journal:  Pharmacoeconomics       Date:  1997-10       Impact factor: 4.981

Review 5.  Why training is the key to successful guideline implementation.

Authors:  A D Paltiel; P J Neumann
Journal:  Pharmacoeconomics       Date:  1997-09       Impact factor: 4.981

6.  Ontario's formulary committee: how recommendations are made.

Authors:  Anne M PausJenssen; Peter A Singer; Allan S Detsky
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

7.  Economic evaluation in healthcare. A brief history and future directions.

Authors:  K Blumenschein; M Johannesson
Journal:  Pharmacoeconomics       Date:  1996-08       Impact factor: 4.981

Review 8.  Development of an economic model for the management of upper gastrointestinal disease in primary care. Preliminary findings.

Authors:  A Haycox; M Butterworth; T Walley; S Barton
Journal:  Pharmacoeconomics       Date:  1998       Impact factor: 4.981

Review 9.  Cost-effectiveness analysis in diagnosis of cardiac disease: overview of its rationale and method.

Authors:  R E Patterson
Journal:  J Nucl Cardiol       Date:  1996 Jul-Aug       Impact factor: 5.952

Review 10.  When are statins cost-effective in cardiovascular prevention? A systematic review of sponsorship bias and conclusions in economic evaluations of statins.

Authors:  Ferrán Catalá-López; Gabriel Sanfélix-Gimeno; Manuel Ridao; Salvador Peiró
Journal:  PLoS One       Date:  2013-07-08       Impact factor: 3.240
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.